Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Purpose
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid and may kill tumor cells. Giving relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma.
Conditions
- Progressive Glioblastoma
- Recurrent Glioblastoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Histologically-proven glioblastoma (World Health Organization [WHO] 2021 criteria)
- Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO)
criteria
- No IDH mutation (IDH1 R132H negative by immunohistochemistry [IHC] or sequencing)
- Patients must be in first recurrence of glioblastoma following radiation therapy and
temozolomide
- No prior therapies except radiation, surgery, temozolomide, Tumor Treating Fields
(TTFields), and/or Gliadel wafers (placed during the first surgery at diagnosis of
glioblastoma multiforme [GBM]). Prior radiation therapy, TTFields, or placement of
Gliadel wafers must be completed at least 2 weeks prior to registration. Prior
temozolomide must be completed at least 3 weeks prior to registration
- No prior use of nivolumab or other anti-PD1 agents
- Patients must be neurologically stable off corticosteroids for at least 5 days prior
to registration
- Age: ≥ 18 years
- Karnofsky Performance Status: ≥ 60% (i.e. patient must be able to care for
themselves with occasional help from others)
- Absolute lymphocyte count (ALC): ≥ 1000/mm^3
- Absolute neutrophil count (ANC): ≥ 1500/mm^3
- Platelet count: ≥ 100,000/mm^3
- Hemoglobin: ≥ 9.0 g/dL
- Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT): ≤
1.5 x upper limit of normal (ULN)
- Total bilirubin: < 2.0 x ULN (Except for patients with Gilbert's syndrome, who must
have direct bilirubin < 2.0 x ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT): < 3.0 x ULN
- Calculated (calc.) creatinine clearance (CrCl): ≥ 50 mL/min
- Calculated by Cockcroft-Gault equation
- Not pregnant and not nursing, because this study involves an investigational agent
whose genotoxic, mutagenic and teratogenic effects on the developing fetus and
newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic
effects. Therefore, for women of childbearing potential only, a negative pregnancy
test done within 14 days prior to registration is required
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- No active brain metastases or leptomeningeal disease
- HIV: HIV-infected patients on effective anti-retroviral therapy with undetectable
viral load within 6 months prior to registration are eligible for this trial
- Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV)
infection, the HBV viral load must be undetectable on suppressive therapy, if
indicated
- Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must have
been treated and cured. For patients with HCV infection who are currently on
treatment, they are eligible if they have an undetectable HCV viral load
- No known medical condition causing an inability to swallow oral formulations of
agents
- No current symptomatic pulmonary disease
- No autoimmune disorders that require systemic treatment (except hyperthyroidism or
diabetes mellitus)
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm I (nivolumab, relatlimab) |
Patients receive nivolumab IV over 30 minutes followed by relatlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study. |
|
|
Active Comparator Arm II (lomustine) |
Patients receive lomustine PO on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study. |
|
Recruiting Locations
Jonesboro, Arkansas 72401
Auburn, California 95602
Duarte, California 91010
Dublin, California 94568
Site Public Contact
877-642-4691
Fremont, California 94538
Fresno, California 93720
Site Public Contact
833-574-2273
Irvine, California 92612
La Jolla, California 92093
Lancaster, California 93534
Long Beach, California 90813
Site Public Contact
877-467-3411
Los Angeles, California 90027
Los Angeles, California 90048
Site Public Contact
310-423-8965
Modesto, California 95356
Site Public Contact
877-642-4691
Modesto, California 95356
Oakland, California 94611
Orange, California 92868
Palo Alto, California 94301
Palo Alto, California 94304
Redwood City, California 94063
Site Public Contact
877-642-4691
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95823
San Diego, California 92120
San Francisco, California 94115
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Rafael, California 94903
Santa Clara, California 95051
Santa Rosa, California 95403
South San Francisco, California 94080
Upland, California 91786
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94598
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Greeley, Colorado 80631
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Bridgeport, Connecticut 06606
Site Public Contact
860-972-4700
Hartford, Connecticut 06102
Site Public Contact
860-545-5363
New Haven, Connecticut 06520
Trumbull, Connecticut 06611
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington D.C., District of Columbia 20016
Aventura, Florida 33180
Site Public Contact
954-461-2180
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Coral Springs, Florida 33065
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Doral, Florida 33166
Hollywood, Florida 33021
Hollywood, Florida 33021
Site Public Contact
305-243-2647
Jacksonville, Florida 32207
Site Public Contact
904-202-7468
Jacksonville, Florida 32224-9980
Site Public Contact
855-776-0015
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
786-596-2000
Miami, Florida 33176
Site Public Contact
305-243-2647
Orlando, Florida 32806
Plantation, Florida 33324
Site Public Contact
305-243-2647
Augusta, Georgia 30912
Honolulu, Hawaii 96819
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83687
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Aurora, Illinois 60506
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Eureka, Illinois 61530
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Galesburg, Illinois 61401
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Oak Lawn, Illinois 60453
Ottawa, Illinois 61350
Palos Heights, Illinois 60463
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Washington, Illinois 61571
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Bettendorf, Iowa 52722
Carroll, Iowa 51401
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Fort Dodge, Iowa 50501
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Waukee, Iowa 50263
Site Public Contact
515-241-3305
Kansas City, Kansas 66160
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Westwood, Kansas 66205
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Brewer, Maine 04412
Site Public Contact
800-987-3005
South Portland, Maine 04106
Baltimore, Maryland 21287
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Brighton, Michigan 48114
Canton, Michigan 48188
Chelsea, Michigan 48118
Detroit, Michigan 48202
Escanaba, Michigan 49829
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Lansing, Michigan 48912
Livonia, Michigan 48154
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Edina, Minnesota 55435
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Columbus, Mississippi 39705
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
City of Saint Peters, Missouri 63376
Creve Coeur, Missouri 63141
St Louis, Missouri 63110
St Louis, Missouri 63128
St Louis, Missouri 63129
St Louis, Missouri 63136
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Bellevue, Nebraska 68123
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Reno, Nevada 89502
Lebanon, New Hampshire 03756
Camden, New Jersey 08103
Site Public Contact
856-325-6757
Edison, New Jersey 08818
Site Public Contact
732-321-7010
Jersey City, New Jersey 07302
Livingston, New Jersey 07039
Long Branch, New Jersey 07740
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
Neptune City, New Jersey 07753
Site Public Contact
732-776-4240
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Newark, New Jersey 07112
Sewell, New Jersey 08080
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Toms River, New Jersey 08755
Albuquerque, New Mexico 87106
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Bay Shore, New York 11706
Site Public Contact
516-734-8896
Brooklyn, New York 11220
Buffalo, New York 14263
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Lake Success, New York 11042
Site Public Contact
516-734-8896
Mineola, New York 11501
New York, New York 10016
New York, New York 10032
Oswego, New York 13126
Rochester, New York 14642
Site Public Contact
585-275-5830
Syracuse, New York 13210
Site Public Contact
315-464-5476
The Bronx, New York 10461
Pinehurst, North Carolina 28374
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Centerville, Ohio 45459
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Columbus, Ohio 43210
Columbus, Ohio 43214
Dayton, Ohio 45409
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Troy, Ohio 45373
West Chester, Ohio 45069
Oklahoma City, Oklahoma 73104
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Ontario, Oregon 97914
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97239
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
East Stroudsburg, Pennsylvania 18301
Erie, Pennsylvania 16505
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Jefferson Hills, Pennsylvania 15025
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Philadelphia, Pennsylvania 19107
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Wexford, Pennsylvania 15090
Charleston, South Carolina 29425
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Salt Lake City, Utah 84112
Burlington, Vermont 05401
Burlington, Vermont 05405
Fairfax, Virginia 22031
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23223
Richmond, Virginia 23226
Richmond, Virginia 23298
Seattle, Washington 98122-5711
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Wheeling, West Virginia 26003
Site Public Contact
304-243-6442
Ashland, Wisconsin 54806
Burlington, Wisconsin 53105
Cudahy, Wisconsin 53110
Eau Claire, Wisconsin 54701
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Janesville, Wisconsin 53548
Kenosha, Wisconsin 53142
Madison, Wisconsin 53718
Madison, Wisconsin 53792
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Mukwonago, Wisconsin 53149
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Weston, Wisconsin 54476
More Details
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Study Contact
Detailed Description
PRIMARY OBJECTIVE: I. To compare the restricted mean survival time (RMST) for overall survival (OS) between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care chloroethylcyclohexylnitrosourea (CCNU) (lomustine). SECONDARY OBJECTIVES: I. To compare the 12-month OS rates between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). II. To compare the restricted mean survival times for progression-free survival (PFS) between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). III. To compare the radiographic response rate between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). IV. To compare the safety/adverse event rate between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes followed by relatlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, magnetic resonance imaging (MRI), and blood sample collection throughout study. ARM II: Patients receive lomustine orally (PO) on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study. After completion of study treatment, patients are followed up every 6 months for up to 5 years from time of randomization.